Atrial Fibrillation in Active Cancer Patients

Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.

NCT Number	NCT04696081
Lead Sponsor	University Hospital, Caen Collaborators: University Hospital, Marseille, France, Hospices Civils de Lyon, France, Centre Francois Baclesse, Caen, France, University Hospital of Saint-Etienne, France, Hôpital Lariboisière Fernand Widal, Paris, France, Institut de Cancérologie de l'Ouest Nantes, France, Fundacion Cardio Onco, Santiago, Chile, University of Newcastle, Australia, University Hospital, Rouen
Conditions	Cancer, Drug Toxicity, Atrial Fibrillation, Cardiovascular Complication
Enrollment	1,000 participants
Start Date	2021-09-01
Primary Completion	2025-09-01 (estimated)
Study Completion	2026-01-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-09